Clene Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Clene wird ein jährliches Gewinn- und Umsatzwachstum von 58.6% bzw. 70% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 58% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -3.5% betragen.

Wichtige Informationen

58.6%

Wachstumsrate der Gewinne

58.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	70.0%
Zukünftige Eigenkapitalrendite	-3.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CLNN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	39	-36	-15	-13	4
12/31/2025	5	-48	-57	-42	5
12/31/2024	0	-44	-41	-30	4
3/31/2024	1	-49	-28	-28	N/A
12/31/2023	1	-50	-31	-30	N/A
9/30/2023	1	-40	-33	-31	N/A
6/30/2023	1	-49	-36	-32	N/A
3/31/2023	1	-28	-40	-35	N/A
12/31/2022	0	-30	-44	-39	N/A
9/30/2022	0	-24	-45	-41	N/A
6/30/2022	0	15	-42	-40	N/A
3/31/2022	1	17	-41	-39	N/A
12/31/2021	1	-10	-36	-35	N/A
9/30/2021	1	-13	-32	-31	N/A
6/30/2021	1	-53	-32	-31	N/A
3/31/2021	0	-55	-25	-25	N/A
12/31/2020	0	-19	-19	-19	N/A
9/30/2020	0	-24	-17	-16	N/A
6/30/2020	0	-19	-12	-12	N/A
3/31/2020	0	-16	-13	-13	N/A
12/31/2019	N/A	-16	-13	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CLNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CLNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CLNNDie Einnahmen des Unternehmens (70% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CLNNDie Einnahmen des Unternehmens (70% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLNN wird voraussichtlich in 3 Jahren unrentabel sein.

Clene Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 30%

Price target decreased by 11% to US$5.00

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

Recent updates

Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome

Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg

Consensus revenue estimates fall by 30%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Price target decreased by 11% to US$5.00

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought US$103k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

New minor risk - Share price stability

Independent Director recently bought US$253k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 27%

Consensus revenue estimates decrease by 53%, EPS upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 10% to US$8.57

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$9.57

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board recently bought US$2.9m worth of stock

High number of new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$10.57

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Investor sentiment deteriorated over the past week

Clene slips 13% as lead asset fails in ALS study

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Consensus estimates of losses per share improve by 12%

Independent Director recently bought US$183k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Investor sentiment deteriorated over the past week

Consensus forecasts updated

CEO, President & Director notifies of intention to sell stock

Clene ALS therapy gets EMA panel backing for orphan drug status

Clene Inc Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

Investor sentiment improved over the past week

Clene Inc.(NasdaqCM:CLNN) dropped from Russell 2500 Value Index

Investor sentiment improved over the past week

Co-Founder & Chief Science Officer notifies of intention to sell stock

Independent Chairman of the Board recently bought US$155k worth of stock

Investor sentiment improved over the past week

Clene Inc. Announces the Presentation of New Data from the its Phase 2 RESCUE-ALS Study at the European Network to Cure ALS (ENCALS) Meeting 2022

Independent Chairman of the Board recently bought US$79k worth of stock